MicrobiomeTrials
  • Search Trials
  • Conditions
  • Learn
  • About
Data source: ClinicalTrials.gov
This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Sign up for updates
Home/Conditions/C. difficile (C. diff)
Condition Guide

C. difficile (C. diff)

The condition where microbiome therapy works best

C. difficile is a dangerous bacterial infection that thrives when the gut microbiome is disrupted — often after antibiotic use. FMT has become a landmark treatment, with cure rates over 90% in clinical trials.

View Recruiting Trials

The Microbiome Connection

How C. difficile (C. diff) relates to gut health

Common Symptoms

  • Watery diarrhea (3 or more times per day)
  • Fever
  • Nausea
  • Abdominal pain or tenderness
  • Loss of appetite

How the Microbiome is Involved

C. diff infection is almost entirely caused by microbiome disruption. Antibiotics wipe out protective gut bacteria, leaving a vacuum that C. difficile colonizes and exploits. Restoring a healthy, diverse microbiome — through FMT or next-generation microbiome therapies like SER-109 — directly displaces C. diff and prevents relapse.

Active Trials

View all 37 trials
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk PatientsPhase 1Recruiting
Clostridioides Difficile InfectionRecurrent Infection
Clostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea in Europe, with over 120,000 cases …
Annecy, FranceEst. completion Jan 7, 2028
View Trial →
Fecal Microbiota Transplantation (FMT) for Clostridium DifficileRecruiting
Clostridium Difficile InfectionClostridioides Difficile Infection
Faecal microbiota transplantation (FMT) is used for Clostridioides difficile infection (CDI) as part of an quality impro…
Aarhus N, DenmarkEst. completion Dec 31, 2029
View Trial →
ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile InfectionPhase 2Recruiting
Clostridium Difficile Infection Recurrence
Single-arm trial to evaluate the safety and efficacy of ACX-362E \[ibezapolstat\] in patients with recurrent C. difficil…
Sacramento, United StatesEst. completion Sep 29, 2027
View Trial →

Related Conditions

Inflammatory Bowel Disease (IBD)
Restoring balance to a disrupted gut
Explore
Ulcerative Colitis
From chronic flares to lasting remission
Explore
Irritable Bowel Syndrome (IBS)
Calming the gut-brain storm
Explore

Get notified about new C. difficile (C. diff) trials

We’ll email you when new recruiting trials for your condition are posted. No spam, ever.